Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoThirteen

- PMLiVE

Novo Nordisk’s Tresiba gaining ground in basal insulin market

Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus

- PMLiVE

Novo’s world-leading insulin plant to get even bigger

Danish firm invests €54m in Kalundborg expansion

- PMLiVE

Ypsomed’s touch screen insulin pump for Novo Nordisk approved by EMA

mylife YpsoPump given green light for use with pump cartridge NovoRapid PumpCart

- PMLiVE

Cost containment and the German market

The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

- PMLiVE

Novo creates online diabetes management resource

Aims to educate UK patients and the public on the signs and impact of hypos

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

- PMLiVE

FDA advisors back Novo Nordisk’s IDeglira combination

Unanimous vote is a step forward for the Tesiba-Victoza injection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links